| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Bacterial targets, specifically Gram-positive bacterial strains. The exact molecular target has not been definitively identified in available literature.
|
|---|---|
| ln Vitro |
WU-FA-01 (0-25 µg/mL, 24 h) inhibits Gram-positive bacteria in a dose-dependent manner, however it does not affect Gram-negative strains in any way [1].
WU-FA-01 exhibits high levels of antibacterial activity against Gram-positive bacterial strains. The specific MIC values against different Gram-positive organisms have not been detailed in the available literature. It also demonstrates some anti-inflammatory activity in vitro. |
| ln Vivo |
WU-FA-01 (2000-8000µg/mL) can successfully prevent TPA-induced skin inflammation and exhibits a dose-dependent inhibitory impact on TPA-induced edema in the mouse ear model [1].
WU-FA-01 (2000-8000 microg/mL) prevents TPA-induced skin inflammation and exhibits a dose-dependent inhibitory effect on TPA-induced edema in the mouse ear model. This demonstrates its in vivo anti-inflammatory efficacy. |
| Enzyme Assay |
As WU-FA-01 is primarily characterized as an antibacterial agent, standard antimicrobial susceptibility testing (AST) would be performed following CLSI or EUCAST guidelines. Minimum inhibitory concentrations (MICs) are determined using broth microdilution or agar dilution methods against a panel of Gram-positive bacterial strains.
|
| Cell Assay |
Antibacterial activity is evaluated using standard broth microdilution assays against Gram-positive bacterial strains. Minimum inhibitory concentrations (MICs) are determined after 18-24 hours of incubation at 37degC. Anti-inflammatory activity in vitro may be assessed using LPS-stimulated macrophage assays measuring cytokine production (e.g., TNF-alpha, IL-6).
|
| Animal Protocol |
Animal/Disease Models: TPA-induced skin inflammation in female Kunming mice[1]
Doses: 2000, 4000 and 8000 µg/mL Route of Administration: 20 µL of acetone-loaded agent topically applied to the right ear Experimental Results: Dramatically diminished TPA-induced ear edema by 48.16%, 113.97% and 137.32%, respectively, at concentrations of 2000, 4000 and 8000 µg/mL. TPA-induced ear edema model in mice: WU-FA-01 (2000-8000 microg/mL) is applied topically or administered systemically to evaluate its anti-inflammatory effects. Ear thickness and edema are measured, and inflammatory markers are assessed. |
| ADME/Pharmacokinetics |
WU-FA-01 has a molecular weight of 604.77 and a molecular formula of C34H₅2O₉. It is a hydrogenated derivative with improved stability compared to WU-FA-00. Detailed pharmacokinetic parameters (absorption, distribution, metabolism, excretion) have not been reported in available literature.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published for WU-FA-01 in standard toxicology studies. As a research compound, it is not intended for human therapeutic use. Preliminary in vivo studies indicate that the compound is tolerated at the tested doses in mouse models.
|
| References |
[1]. Pan-Pan Wu, et al. The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. Infect Drug Resist. 2018 Oct 24;11:1945-1957.
|
| Additional Infomation |
WU-FA-01 is a hydrogenated analog of WU-FA-00, an antibacterial agent with anti-inflammatory properties. It is primarily used in antimicrobial and anti-inflammatory research. The compound is for research use only and has not entered clinical trials or received regulatory approval.
|
| CAS # |
882429-53-0
|
|---|---|
| Appearance |
White to off-white solid
|
| SMILES |
C[C@@]12[C@@]3([C@](C[C@H]([C@@]1([H])[C@@]4([C@@]([C@@H]([C@@H](CC4)O)C)([H])CC2)C)O)([H])/C([C@H](C3)OC(C)=O)=C(CCC=O)/C(OCOC(C(C)(C)C)=O)=O)C
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~165.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
